Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Duke Medical Center, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Sidney Kimmel Comprehensive Cancer Center, Oregon Health & Science University, UCSF Helen Diller Family Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Takeda Oncology (United States), U-M Rogel Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2599514945